RGLS — Regulus Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- $183.30m
- $160.87m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 6.83 | 10 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 23.7 | 24.2 | 27.8 | 28.2 | 31.1 |
Operating Profit | -16.8 | -14.2 | -27.8 | -28.2 | -31.1 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -18.6 | -15.7 | -27.8 | -28.3 | -30 |
Provision for Income Taxes | |||||
Net Income After Taxes | -18.6 | -15.7 | -27.8 | -28.3 | -30 |
Net Income Before Extraordinary Items | |||||
Net Income | -18.6 | -15.7 | -27.8 | -28.3 | -30 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -18.6 | -15.7 | -27.8 | -28.3 | -30 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -10.8 | -4.5 | -3.24 | -1.86 | -1.58 |